



WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)		NO 98/10088
<b>(51) International Patent Classification:</b> <span style="float: right;">A1</span> <b>C12N 5/86, 7/01</b>	<b>(11) International Publication Number:</b> <span style="float: right;">12 March 1998 (12.03.98)</span> <b>(43) International Publication Date:</b>	
<b>(21) International Application Number:</b> PCT/US97/15716 <b>(22) International Filing Date:</b> 4 September 1997 (04.09.97)  <b>(30) Priority Data:</b> 60/024,699 6 September 1996 (06.09.96) US  <b>(60) Parent Application or Grant</b> <b>(63) Related by Continuation</b> US 60/024,699 (CON) Filed on 6 September 1996 (06.09.96)	<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (AM, AZ, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BI, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
<b>(71) Applicant (for all designated States except US):</b> TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA [US/US]; Suite 300, 3700 Market Street, Philadelphia, PA 19104-3147 (US).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> WILSON, James, M. [US/US]; 1350 N. Avignon Drive, Galdwyne, PA 19035 (US); CHEN, Nancie [CN/US]; Apartment C5, 174 S. Bethlehem Pike, Ambler, PA 19002 (US).		
<b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>		
<b>(54) Title:</b> AN INDUCIBLE METHOD FOR PRODUCTION OF RECOMBINANT ADENO-ASSOCIATED VIRUSES UTILIZING T7 POLYMERASE		
<b>(57) Abstract</b> <p>Methods for efficient production of recombinant AAV are described. In one aspect, three vectors are introduced into a host cell. A first vector directs expression of T7 polymerase. A second vector carries rep and cap under the control of the T7 promoter. A third vector contains a minigenome flanked by AAV ITRs. In a second aspect, the host cell is stably transfected to contain a plasmid bearing one of the required vector components and the host cell is doubly transfected/infected.</p>		
<pre> graph TD     pT7[<b>pT7 repcap</b>] --&gt; <b>ClaI/EagI digestion</b>  frag1[ ]     pAdLink[<b>pAd.link</b>] --&gt; <b>ClaI/SalI digestion</b>  frag2[ ]     frag1 --&gt; <b>Ligation</b>  frag3[ ]     frag2 --&gt; <b>Ligation</b>  frag3     frag3 --&gt; <b>Fill-in the sticky ends of EagI and salI</b>  frag4[ ]     frag4 --&gt; <b>Ligation</b>  pAdT7[<b>pAd.T7 repcap</b>]     pAdT7 --&gt; <b>NheI linearized</b>  frag5[ ]     pAdDeS27[<b>pAd.deS27</b>] --&gt; <b>ClaI linearized</b>  frag6[ ]     frag5 --&gt; <b>Co-transfection</b>  frag7[ ]     frag6 --&gt; <b>Co-transfection</b>  frag7     frag7 --&gt; <b>plaque purification</b>  frag8[ ]     frag8 --&gt; <b>T7 repcap Adenovirus</b>  frag9[ ]       </pre>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

AN INDUCIBLE METHOD FOR PRODUCTION OF RECOMBINANT  
ADENO-ASSOCIATED VIRUSES UTILIZING T7 POLYMERASE

Background of the Invention

Adeno-associated virus is a replication-  
5 deficient parvovirus, the genome of which is about 4.6 kb  
in length, including 145 nucleotide inverted terminal  
repeats (ITRs). The single-stranded DNA genome of AAV  
contains genes responsible for replication (rep) and  
formation of virions (cap).

10 When this nonpathogenic human virus infects a  
human cell, the viral genome integrates into chromosome  
19 resulting in latent infection of the cell. Production  
of infectious virus and replication of the virus does not  
occur unless the cell is coinfectd with a lytic helper  
15 virus such as adenovirus or herpesvirus. Upon infection  
with a helper virus, the AAV provirus is rescued and  
amplified, and both AAV and helper virus are produced.

AAV possesses unique features that make it  
attractive as a vector for delivering foreign DNA to  
20 cells. Various groups have studied the potential use of  
AAV in the treatment of disease states.

However, an obstacle to the use of AAV for  
delivery of DNA is the lack of highly efficient methods  
for encapsidation of recombinant genomes. See, R. Kotin,  
25 Hum. Gene Ther., 5:793-801 (1994). Furthermore, the rep  
gene product is toxic to cells and thus cannot be  
expressed at high levels. For example, previously known  
methods employ transfection of host cells with a rAAV  
genome which lacks rep and cap genes followed by co-  
30 infection with wild-type AAV and adenovirus. However,  
this method leads to unacceptably high levels of wild-  
type AAV. Incubation of cells with rAAV in the absence  
of contaminating wild-type AAV or helper adenovirus is  
associated with little recombinant gene expression. And,  
35 in the absence of the AAV rep gene product, integration  
is inefficient and not directed to chromosome 19.

Bacteriophage T7 RNA polymerase (T7 Pol) is the product of T7 gene 1, which can recognize its responsive promoter sequence specifically and exhibit a high transcriptase activity [M. Chamberlin et al, Nature, 228:227-231 (1970); J. Dunn and F. Studier, J. Mol. Biol., 166:447-535 (1983); and B. Moffatt et al, Cell, 49:221-227 (1987)]. It has been used for heterologous expression of proteins in *E. coli* [S. Tabor and C. Richardson, Proc. Natl. Acad. Sci. USA, 82:1074-1078 (1985); F. Studier and B. Moffatt, J. Mol. Biol., 189:113-130 (1986)], in recombinant vaccinia virus-infected eukaryotic cells [T. Fuerst et al, Proc. Natl. Acad. Sci. USA, 83:8122-8126 (1986); A. Ramsey-Ewing and B. Moss, J. Biol. Chem., 271:16962-16966 (1996)], and in mammalian cells [A. Lieber et al, Nucl. Acids Res., 17:8485-8493 (1989)].

What is needed is an efficient method for production of rAAV which avoids the problems associated with rep toxicity for the packaging cell.

#### 20 Summary of the Invention

The present invention provides an inducible method for efficient production of rAAV which makes use of T7 polymerase. T7 Pol is derived from lambda phage and its promoter is not active in mammalian cells. Thus, expression of rep/cap can be controlled by placing these genes under control of the T7 promoter and providing the T7 Pol in trans or under the control of an inducible promoter. Thus, this method avoids the toxic effects of rep which rendered prior art methods of producing rAAV inefficient. The method of the invention is particularly suitable for large scale production of rAAV, which is desired for rAAV vectors to be used in gene therapy.

In one aspect, the invention provides a method of producing rAAV which utilizes three vectors. A first

vector is capable of expressing T7 polymerase in the host cell following transfection or infection. A second vector comprises the AAV *rep* and *cap* genes under the control of T7 promoter sequences (T7/*rep/cap*). The third  
5 vector comprises a cassette containing 5' and 3' AAV inverted terminal repeats (ITRs) flanking a selected transgene. A host cell containing these three vectors is cultured under conditions which permit replication and packaging of a recombinant AAV, and the rAAV is  
10 recovered.

In another aspect, the invention provides a method in which a host cell is stably transfected with one of the three components of the system used in the triple infection system. The remaining components are  
15 introduced into the host cell, as described above.

In one embodiment, the invention provides a method in which a vector containing T7/*rep/cap* and a vector containing a cassette comprising a selected minigene flanked by 5' and 3' AAV ITRs are introduced  
20 into a host cell expressing T7 polymerase. The host cell is then cultured under conditions which permit production of rAAV. In another embodiment, this invention provides a method which utilizes a host cell stably transfected with a plasmid containing T7/*rep/cap*. A vector  
25 containing T7 pol and a vector containing a cassette comprising 5' AAV inverse terminal repeat (ITR), a selected minigene, and 3' AAV ITR are introduced into the host cell. The host cell is cultured under conditions which permit production of rAAV. In still another  
30 embodiment, the invention provides a method which utilizes a host cell stably transfected with a rescuable rAAV cassette. A vector containing T7 pol and a vector containing T7/*rep/cap* are introduced into the host cell. The host cell is cultured under conditions which permit  
35 production of rAAV.

In yet another aspect, the present invention provides a method which utilizes a host cell stably transfected with two of the three components of the system used in the triple infection system. The remaining component is then introduced into the host cell, as described above.

In a further aspect, the present invention provides a method which utilizes a host cell stably transfected with the three components of the system used in the triple infection system. In this aspect, the T7 Pol is controlled by an inducible promoter.

In still a further aspect, the invention provides a rAAV produced according to the method of the invention.

Other aspects and advantages of the present invention are described further in the following detailed description of the preferred embodiments thereof.

#### Brief Description of the Drawings

Fig. 1 provides a schematic illustration of the construction of a recombinant adenovirus containing the T7 polymerase gene.

Fig. 2 provides a schematic illustration of the construction of a recombinant plasmid containing the AAV rep/cap genes under control of a T7 promoter.

Fig. 3 provides a schematic illustration of the construction of a recombinant adenovirus containing the rep/cap genes under control of a T7 promoter.

Fig. 4 provides a schematic illustration of the construction of a recombinant hybrid Ad/AAV virus.

#### Detailed Description of the Invention

The invention provides an inducible method for efficient production of recombinant AAV vectors useful particularly for gene delivery and transfer.

Specifically, the invention provides methods of AAV production in which expression of the toxic but necessary rep gene is controlled by the T7 promoter.

Thus, in one aspect, the method of the invention for production of rAAV involves introducing into a host cell the AAV rep and cap genes under control of a T7 promoter, and a recombinant adeno-associated virus (rAAV) cassette containing a selected minigene flanked by AAV ITRs. Upon introduction of a gene encoding T7 pol, high level expression of rep protein from the T7/rep/cap construct is induced and cells may be grown on a large scale. When rep expression is desired, the cells are caused to express the T7 polymerase which acts on the T7 promoter. This facilitates the efficient replication and packaging of rAAV carrying a gene of interest.

A host cell may be triple transfected (or infected) with vectors containing the above elements. Alternatively, a host cell which expresses one or more of the required elements and may be transfected/infected with the remaining elements is utilized. In another alternative, a host cell is utilized which stably expresses all three elements of the system, and the T7 pol is placed under the control of an inducible promoter, which permits rep/cap expression to be controlled and the avoidance of toxic effects to the cell.

For each of the vector components used in the method of the invention, adenoviral constructs are currently preferred. However, using the information provided herein and known techniques, one of skill in the art could readily construct a different viral (adenoviral or non-adenoviral) or a plasmid vector which is capable of driving expression of the desired genes in the host cell. For example, although less preferred because of their inability to infect non-dividing cells, vectors

carrying the required elements of this system, e.g., the T7 polymerase, may be readily constructed using retroviruses. Therefore, this invention is not limited by the virus or plasmid selected for purposes of introducing the T7 pol, T7/rep/cap, or AAV cassette into the host cell. Desirably, at least one of the vectors is a virus which provides the necessary helper functions to enable packaging. Alternatively, the helper functions may be provided by a co-transfected adenovirus or herpesvirus. Suitable techniques for introducing these vectors into the host cell are discussed below and are known to those of skill in the art. As used herein, a "host cell" is any cell (cell line), preferably mammalian, which permits expression of the T7 pol and T7/rep/cap and packaging of the rAAV containing the cassette, under the conditions described herein. Suitable packaging cells are known, and may be readily selected by the skilled artisan.

#### A. Triple Infection/Transfection

As stated above, a host cell used for assembly and packaging of recombinant AAV may be transfected with plasmid vectors or infected with viral vectors containing the required components of the system.

##### 1. T7 Pol Vectors

In a preferred embodiment, a first vector contains the T7 Pol gene under the control of a suitable promoter. In example 5 below, the nuclear localized T7 Pol gene is obtained from a publicly available plasmid [M. Strauss, Nucleic Acid Res., 17:8485-8493 (1989)]. However, the gene may alternatively be obtained from other commercial and academic sources, including the American Type Culture Collection (PTF7-3, Accession No. 484944). See, also GenBank accession number M30308. Desirably, the T7 pol



gene is linked to a nuclear localization signal, such as that described in Dunn, Gene, 68:259-266 (1988), using conventional techniques.

Desirably, T7 Pol is under the control of a cytomegalovirus (CMV) immediate early promoter/enhancer [see, e.g., Boshart et al, Cell, 41:521-530 (1985)]. However, other suitable promoters may be readily selected by one of skill in the art. Useful promoters may be constitutive promoters or regulated (inducible) promoters, which will enable control of the amount of the transgene to be expressed. For example, another suitable promoter includes, without limitation, the Rous sarcoma virus LTR promoter/enhancer. Still other promoter/enhancer sequences may be selected by one of skill in the art.

In addition, the vector also includes other conventional regulatory elements necessary to drive expression of T7 Pol in a cell transfected with the vector. Such regulatory elements are known to those of skill in the art.

## 2. T7/Rep/Cap Vectors

The second vector component of this system contains the rep and cap genes under control of a T7 promoter. The rep and cap genes can be obtained from a variety of known sources. See, e.g., T. Shenk, J. Virol., 61:3096-3101 (1987), which provides the AAV2 genome within the plasmid psub201; E. W. Lusby et al, J. Virol., 41:518-526 (1982) and J. Smuda and B.J. Carter, Virology, 184:310-318 (1991).

Similarly, the T7 promoter sequences [J. J. Dunn and F.W. Studier, J. Mol. Biol., 166:477-535 (1983)] may be obtained from a variety of commercial and academic sources. In a preferred embodiment, the vector further contains the sequence of untranslated region (UTR) of encephalomyocarditis (EMCV) downstream of the T7

promoter. The inventors believe this sequence increases expression of the gene 5- to 10-fold.

In addition, the vector also includes conventional regulatory elements necessary to drive expression of the rep/cap in a cell transfected with the vector. Such regulatory elements are known to those of skill in the art.

3. *RAAV Cassette (Template)*

The third vector component contains a RAAV cassette containing a minigene flanked by AAV ITRs. As discussed in more detail below, such a minigene contains a suitable transgene, a promoter, and other regulatory elements necessary for expression of the transgene.

The AAV sequences employed are preferably limited to the cis-acting 5' and 3' inverted terminal repeat (ITR) sequences [See, e.g., B. J. Carter, in "Handbook of Parvoviruses", ed., P. Tijsser, CRC Press, pp.155-168 (1990)]. Desirably, substantially the entire 143 bp sequences encoding the ITRs are used in the vectors. Some degree of minor modification of these sequences is expected to be permissible for this use. The ability to modify these ITR sequences is within the skill of the art. See, e.g., texts such as Sambrook et al, "Molecular Cloning. A Laboratory Manual.", 2d edit., Cold Spring Harbor Laboratory, New York (1989). Alternatively, it may be desirable to use functional fragments of the ITRs. Such fragments may be determined by one of skill in the art.

The AAV ITR sequences may be obtained from any known AAV, including presently identified human AAV types. Similarly, AAVs known to infect other animals may also be employed in the vector constructs of this invention. The selection of the AAV is not anticipated to limit the following invention. A variety of AAV

strains, types 1-4, are available from the American Type Culture Collection or available by request from a variety of commercial and institutional sources. In the following exemplary embodiment an AAV-2 is used for convenience.

The 5' and 3' AAV ITR sequences flank a minigene which is made up of a selected transgene sequence and associated regulatory elements. The transgene sequence of the vector is a nucleic acid sequence heterologous to the AAV sequence, which encodes a polypeptide or protein of interest. The transgene is operatively linked to regulatory components in a manner which permits transgene transcription.

The composition of the transgene sequence will depend upon the use to which the resulting vector will be put. For example, one type of transgene sequence includes a reporter sequence, which upon expression produces a detectable signal. Such reporter sequences include without limitation an *E. coli* beta-galactosidase (*LacZ*) cDNA, an alkaline phosphatase gene and a green fluorescent protein gene. These sequences, when associated with regulatory elements which drive their expression, provide signals detectable by conventional means, e.g., ultraviolet wavelength absorbance, visible color change, etc. A more preferred transgene sequence includes a therapeutic gene which expresses a desired gene product in a host cell. These therapeutic nucleic acid sequences typically encode products which may be administered to a patient *in vivo* or *ex vivo* to replace or correct an inherited or non-inherited genetic defect or treat an epigenetic disorder or disease. The selection of the transgene sequence is not a limitation of this invention.

In addition to the major elements identified above, the minigene also includes conventional regulatory elements necessary to drive expression of the transgene in a cell transfected with the vector carrying the AAV cassette. Thus the minigene contains a selected promoter which is linked to the transgene and located within the minigene, between the AAV ITR sequences of the vector.

Selection of the promoter which mediates expression of the transgene is a routine matter and is not a limitation of the vector. Useful promoters include those which are discussed above in connection with the first vector component.

The minigene will also desirably contain heterologous nucleic acid sequences including sequences providing signals required for efficient polyadenylation of the transcript and introns with functional splice donor and acceptor sites. A common poly-A sequence which is employed in the exemplary vectors of this invention is that derived from the papovavirus SV-40. The poly-A sequence generally is inserted following the transgene sequences and before the 3' AAV ITR sequence. A common intron sequence is also derived from SV-40, and is referred to as the SV-40 T intron sequence. A minigene of the present invention may also contain such an intron, desirably located between the promoter/enhancer sequence and the transgene. Selection of these and other common vector elements are conventional and many such sequences are available [see, e.g., Sambrook et al, and references cited therein].

The rAAV vector containing the AAV ITRs flanking the minigene may be carried on a plasmid backbone and used to transfect a selected host cell or may be flanked by viral sequences (e.g., adenoviral sequences) which permit it to infect the selected host

cell. Suitable Ad/AAV recombinant viruses may be produced in accordance with known techniques. See, e.g., WO 96/13598, WO 95/23867, and WO 95/06743, which are incorporated by reference herein.

5           B. *Double Infection/Transfection*

A cell line which stably expresses T7 pol may be constructed, and then double transfected (or infected) with a vector containing T7/rep/cap and a vector containing a rAAV cassette, as illustrated in the following table (Inf = infection and Txf = transfection).

	<u>T7 rep/cap</u>	<u>rAAV</u>
System A	Inf	Inf
System B	Inf	Txf
System C	Txf	Inf
15 System D	Txf	Txf

Alternatively, a cell line stably transfected with T7 rep/cap may be double transfected (infected) with a vector carrying T7 pol and a vector carrying the rAAV cassette, as illustrated in the following table.

	<u>T7 Pol</u>	<u>rAAV</u>
System E	Inf	Inf
System F	Inf	Txf
System G	Txf	Inf
25 System H	Txf	Txf

In still another alternative, a cell line which contains a rescuable rAAV cassette may be double transfected (infected) with a vector containing T7 Pol and a vector containing T7/rep/cap, as illustrated in the following table.

	<u>T7 Pol</u>	<u>T7 rep/cap</u>
System I	Inf	Inf
System J	Inf	Txf
System K	Txf	Inf
35 System L	Txf	Txf

The plasmid and viral vectors used in double transfection/infection steps are as described above in connection with the triple transfection and/or infection system.

- 5 A stable cell line of the invention can be produced by transfection of a desired cell, e.g., 293 cells or other packaging cell lines expressing required adenoviral genes, with a plasmid containing the desired gene, e.g., T7 Pol, using conventional techniques and  
10 selected via an accompanying resistant marker gene. Depending upon whether inducible or constitutive expression is desired, an appropriate promoter may be selected. For example, if a host cell inducibly expressing T7 Pol is desired, the cell may be transfected  
15 with a plasmid containing T7 Pol under control of a metallothionein promoter. Alternatively, if a host cell constitutively expressing T7 Pol is desired, it may be inserted under control of a RSV or CMV promoter. Similar techniques may be used for providing a host cell  
20 containing the T7/rep/cap and a host cell containing a rescuable rAAV. The examples below describe production of stable cell lines. However, one of skill in the art could readily produce such cell lines using other conventional techniques. See, generally, Ausubel et al,  
25 Current Protocols in Molecular Biology (Wiley Interscience 1987).

C. *Single Infection/Transfection*

- A cell line which stably expresses two of the components of this system may be constructed, and  
30 then transfected (or infected) with a vector containing the remaining component of the system, as described above. For example, using the techniques described herein, a cell line is utilized which is stably transfected with the T7/rep/cap and a rescuable rAAV.  
35 The cell line is then transfected or infected with a

vector containing the T7 pol. As another example, the cell line is stably transfected with the T7 pol and a rescuable rAAV. The cell line is then transfected or infected with a vector containing the T7 rep/cap.

5           D. *Cell Line Containing T7 Pol, rAAV and T7/rep/cap*

A cell line which stably expresses all three of the components of this system may be constructed and utilized in the method of the invention. Using known techniques, a suitable packaging cell line is constructed which contains the rAAV, the T7/rep/cap and the T7 pol. In this embodiment, the T7 Pol is placed under the control of an inducible promoter. Suitable inducible promoters are known to those of skill in the art and are discussed herein. For example, T7 Pol may be placed under control of a metallothionein promoter. In this manner, expression of the T7 Pol, and thus the rep/cap, which are under control of the T7 promoter can be regulated and toxic effects to the cell avoided.

20           E. *Production of Vectors and rAAV*

Assembly of the selected DNA sequences of the adenovirus, AAV and the reporter genes or therapeutic genes and other vector elements into the vectors described above utilize conventional techniques. Such techniques include cDNA cloning such as those described in texts [Sambrook et al, cited above], use of overlapping oligonucleotide sequences of the adenovirus or AAV genome, polymerase chain reaction, and any suitable method which provides the desired nucleotide sequence.

Whether using the three vector system, or stably infected cells, introduction of the vectors into the host cell is accomplished using known techniques. Where appropriate, standard transfection and co-transfection techniques are employed, e.g., CaPO<sub>4</sub>.

transfection techniques using the complementation human embryonic kidney (HEK) 293 cell line (a human kidney cell line containing a functional adenovirus Ela gene which provides a transacting Ela protein). Other conventional methods employed in this invention include homologous recombination of the viral genomes, plaquing of viruses in agar overlay, methods of measuring signal generation, and the like.

Following infection/transfection, the host cell is then cultured under standard conditions, to enable production of the rAAV. See, e.g., F. L. Graham and L. Prevec, Methods Mol. Biol., 7:109-128 (1991). Desirably, once the rAAV is identified using conventional techniques, it may be isolated using standard techniques and purified.

These examples illustrate the preferred methods of the invention. These examples are illustrative only and do not limit the scope of the invention.

#### Example 1 - Construction of a T7 Pol Adenovirus

Figure 1 provides a schematic of the construction of the recombinant adenovirus carrying the T7 polymerase.

The plasmid pMTT7N was obtained from Dr. Michael Strauss [A. Lieber et al, Nucl. Acids Res., 17:8485-8493 (1989)]. pMTT7N contains a N-terminal nuclear location signal of SV40 large T antigen fused to the T7 Pol gene (T7N Pol) which is linked to the polyadenylation sequence of SV40. Expression is driven by the inducible mouse metallothionein promoter.

The pMTT7N plasmid DNA was digested with BglII and PvuII restriction enzymes and the fragments separated on an agarose gel. The BglII/PvuII T7 Pol DNA fragment was ligated to the BglII/EcoRV cleaved vector pAd.CMV.link.1 to form pAd.CMV.T7N. pAd.CMV.link.1 is a



plasmid containing the adenoviral sequences 0 to 16 map units deleted of Ela and Elb into which a CMV promoter-polylinker cassette was cloned. This is described in X. Ye et al, J. Biol. Chem., 271:3639-3646 (1996).

In pAd.CMV.T7N, the expression unit of T7 Pol is directed by the CMV promoter. The promoter for the T7 Pol gene is linked to a PolyA tail as a cassette within the sequence of adenovirus 0-1 map unit (mu) and 9-16 mu. The pAd.CMV.T7N is linearized by Nhe I digestion and co-transfected with Cla I linearized Addel327 backbone using Cellphate kit (Pharmacia). Approximately 1 week post-transfection, the T7 Pol adenovirus can be isolated from the plaques for further purification.

#### 15 Example 2 - Cell Lines Expressing T7 Pol

A cell line stably expressing T7 Pol is established by co-transfection of plasmids pMTT7N and pMTCB6+ (which provides a selective marker) [K. H. Choo et al, DNA, 5:529-538; Eur. J. Biochem., 174:417-424] into 293 cell at a ratio of 10:1 using calcium phosphate precipitation [F. Graham and A. van der Eb, Virology, 52:456-467 (1973)]. Colony cloning is carried out by Geneticin selection at a concentration of 1 mg/ml. Each clone obtained is transfected with pT7 rep/cap plasmid [see, Example 3 below] and analyzed for its ability to induce the expression of Rep protein upon induction by supplementation with Zn<sup>++</sup>.

To establish a stable cell line that constitutively expresses the T7 Pol, the T7N Pol (obtained by BglII/PvuII digestion of pMTT7N, as described above) was subcloned downstream of RSV promoter at the cloning sites of BamHI and PvuII in the vector of pEBVhis [Invitrogen]. The resulting plasmid, designated pEBVhisT7N, was transfected into 293 cells and selected

with Hygromycin at a concentration of 400 µg/ml. Each positive clone is analyzed for the presence of T7 Pol by its ability to produce expression of T7-LacZ or T7-rep/cap in cells transfected with these plasmids.

5 Example 3 - Production of T7 rep/cap Adenovirus

The production of this recombinant adenoviral vector is illustrated schematically in Figs. 2 and 3.

A. Plasmid Construction

- 10 The plasmid pTM1 [B. Moss et al, Nature, 348:91-92 (1990)], designed for expressing genes under control of the T7 promoter/EMCV UTR (untranslated region of encephalomyocarditis), was used as the vector for expressing AAV rep/cap. The entire coding sequence of rep/cap was separated into two portions by the unique  
15 SacI site and subcloned into the pTM1 plasmid as described below.

- Because there is no appropriate restriction enzyme existing between the initiation site of rep and its natural promoter, p5, the left end of the  
20 rep sequence (N-rep) was first amplified by PCR. The sequence of the upper primer was SEQ ID NO:2: TATTTAAGCCCCGAGTGAGCT (from position of 255 to 274) which introduced a nucleotide substitution A→T at position 274 (underlined). A SacI site was then generated to permit  
25 the cloning of N-rep into pTM1 and in-frame expression of Rep protein from the EMCV UTR preferred initiation site (within the NcoI site). The PCR product (739 bp in length) was directly cloned into pCR2.1 vector (Invitrogen) and named pCR-N-rep.

- 30 The pTM-1 plasmid was digested with SacI and Stu I restriction enzymes and ligated with a 3.7 kb SacI/SnaBI fragment from psub201 [Samulski et al, J. Virol., 61:3096-3101 (1987)] containing the right end of the AAV genome (without ITR sequence), i.e., the c-

terminal portion of rep and full-length cap sequence. This T7 promoter-driven rep/cap construct is named pT7-c-rep/cap.

The first 535 bp sequence of rep was removed from the pCR-N-Rep plasmid by SacI digestion and subcloned into pT7-C-rep/cap, which has similarly been digested with SacI and subjected to alkaline phosphatase treatment to prevent self-ligation of the vector. The final construct was named pT7 rep/cap which contains the full length coding sequence of rep/cap downstream of T7 promoter/EMCV UTR, followed by the T7 terminating sequence.

B. *Production T7 rep/cap Adenovirus*  
pAd.link is a construct similar to pAd.CMV.link, a plasmid containing the adenoviral sequences 0 to 16 map units deleted of Ela and Elb as described in the other adenovirus vectors into which a CMV promoter-polylinker cassette was cloned and described in X. Ye et al, *J. Biol. Chem.*, 271:3639-3646 (1996). However, pAd.link contains no CMV promoter or polyA tail sequence.

The entire region including the T7 promoter, EMCV UTR, rep/cap and T7 terminating sequence was excised from pT7 rep/cap by digestion with ClaI and EagI, and then subcloned into the adenoviral sequences of pAd.link, which had previously been subjected to ClaI/SalI digestion, after filling in the sticky ends of EagI and SalI by Klenow polymerase. The resulting plasmid is designated pAd.T7 rep/cap.

The pAd.T7 rep/cap is co-transfected with the ClaI linearized Ad.del327 backbone DNA into 293 cell for the generation of T7 rep/cap adenovirus.

Example 4 - Cell Line Expressing rep/cap

A cell line stably transfected with pT7 rep/cap is established by transfection of pMTCB6+ into 293 cell at ratio of 10:1 and selected with Geneticin. Each clone is analyzed for the presence of rep protein by transfection with T7 Pol expressing plasmid.

Example 5 - Production of Recombinant AAV Hybrid Vector

Plasmid pAV.CMVlacZ serves as a template for rAAV to be replicated and packaged in the presence of AAV non-structural and capsid proteins.

Plasmid AV.CMVlacZ is a rAAV cassette in which rep and cap genes are replaced with a minigene expressing  $\beta$ -galactosidase from a CMV promoter. The linear arrangement of AV.CMVlacZ includes:

(a) the 5' AAV ITR (bp 1-173) obtained by PCR using pAV2 [C. A. Laughlin et al, *Gene*, 22: 65-73 (1983)] as template [nucleotide numbers 365-538 of SEQ ID NO:1];

(b) a CMV immediate early enhancer/promoter [Boshart et al, *Cell*, 41:521-530 (1985); nucleotide numbers 563-1157 of SEQ ID NO:1],

(c) an SV40 intron (nucleotide numbers 1178-1179 of SEQ ID NO:1),

(d) *E. coli* beta-galactosidase cDNA (nucleotide numbers 1356 - 4827 of SEQ ID NO:1),

(e) an SV40 polyadenylation signal (a 237 BamHI-BclI restriction fragment containing the cleavage/poly-A signals from both the early and late transcription units; nucleotide numbers 4839 - 5037 of SEQ ID NO:1) and

(f) 3'AAV ITR, obtained from pAV2 as a SnaBI-BglIII fragment (nucleotide numbers 5053 - 5221 of SEQ ID NO:1).

Where desired, the LacZ gene can be replaced with a desired therapeutic or other transgene for the purpose of generating new rAAV. See, Fig. 4. The sequence including CMV directed LacZ reporter cassette in  
5 between two AAV ITR sequences is excised from pAV.CMV.LacZ by PvuII digestion. This fragment is ligated with the EcoRV treated pAd.link to generate the plasmid pAd.AV.CMV.LacZ. This plasmid is co-transfected with ClaI linearized Addel327 backbone DNA to generate an  
10 adeno-rAAV hybrid virus.

Example 6 - Cell line containing rescuable, integrated rAAV template

293 cells are transfected/infected with pAV.CMV.LacZ/rAAV Ad hybrid virus to generate cell line  
15 that has incorporated rAAV, as determined by analysis of the genomic DNA by Southern blot. The clone is examined for the rescue of rAAV template by transfection/infection with rep/cap expressing constructs.

Numerous modifications and variations of the  
20 present invention are included in the above-identified specification and are expected to be obvious to one of skill in the art. Such modifications and alterations to the processes of the present invention are believed to be encompassed in the scope of the claims appended hereto.

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

- (i) APPLICANT: Trustees of the University of Pennsylvania  
Wilson, James M.  
Chen, Nancie N.
- (ii) TITLE OF INVENTION: An Inducible Method for Production of  
Recombinant Adeno-Associated Viruses Utilizing T7  
Polymerase
- (iii) NUMBER OF SEQUENCES: 2
- (iv) CORRESPONDENCE ADDRESS:
  - (A) ADDRESSEE: Howson and Howson
  - (B) STREET: Spring House Corporate Cntr, PO Box 457
  - (C) CITY: Spring House
  - (D) STATE: Pennsylvania
  - (E) COUNTRY: USA
  - (F) ZIP: 19477
- (v) COMPUTER READABLE FORM:
  - (A) MEDIUM TYPE: Floppy disk
  - (B) COMPUTER: IBM PC compatible
  - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
  - (D) SOFTWARE: PatentIn Release #1.0, Version #1.30
- (vi) CURRENT APPLICATION DATA:
  - (A) APPLICATION NUMBER: WO
  - (B) FILING DATE:
  - (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
  - (A) APPLICATION NUMBER: US 60/024,699
  - (B) FILING DATE: 06-SEP-1996
- (viii) ATTORNEY/AGENT INFORMATION:
  - (A) NAME: Kodroff, Cathy A.
  - (B) REGISTRATION NUMBER: 33,980
  - (C) REFERENCE/DOCKET NUMBER: GNVPM.022CIP1PCT
- (ix) TELECOMMUNICATION INFORMATION:
  - (A) TELEPHONE: 215-540-9200
  - (B) TELEFAX: 215-540-5818

## (2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 10398 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: double
  - (D) TOPOLOGY: unknown
- (ii) MOLECULE TYPE: cDNA

## (x1) SEQUENCE DESCRIPTION: SEQ ID NO:1:

GAATTGGCTA GCATCATCAA TAATATACT TATTTGGAT TGAAGCCAAT ATGATAATGA	60
GGGGGTGGAG TTTGTACGT GGGCGGGGC GTGGGAACGG GCGGGGTGAC GTAGTAGTGT	120
GGCGGAAGTG TGATGTTGCA AGTGTGGCG AACACATGTA AGCGACGGAT GTGGCAAAAG	180
TGACGTTTTT GGTGTGCGCC GGTGTACACA GGAAGTGACA ATTTTCGCGC GGTTTTAGGC	240
GGATGTTGTA GTAAATTTGG GCGTAACCGA GTAAGATTTC GCCATTTCG CGGGAAAAC	300
GAATAAGAGG AAGTGAATC TGAATAATT TGTGTTACTC ATAGCGCGTA ATATTGTCT	360
AGGGAGATCT GCTGCGCGCT CGCTCGCTCA CTGAGGCGCG CCGGGCAAAG CCGGGCGCTC	420
GGCGGACCTT TGGTGGCGCG GCGTCAGTGA GCGAGCGAGC GCGCAGAGAG GGAATGGCCA	480
ACTCCATCAC TAGGGGTTCC TTGTAGTTAA TGATTAACCC GCCATGCTAC TTATCTACAA	540
TTGAGCTTG CATGCGTGCA GGTGCTTACA TAACTTACGG TAAATGGCCC GCGTGGCTGA	600
CGGCCCAACG ACCCGCGCCC ATTGACGTCA ATAATGACGT ATGTTCCCAT AGTAACGCCA	660
ATAGGGACTT TCCATTGACG TCAATGGGTG GAGTATTTC GGTAACTGC CCACTTGGCA	720
GTACATCAAG TGATCATAT GCCAATACG CCCCCTATTG ACGTCAATGA CGTAAATGG	780
CCCGCTGGC ATTATGCCA GTACATGACC TTATGGGACT TTCTACTTG GCAGTACATC	840
TACGTATTAG TCATCGCTAT TACCATGGTG ATGCGGTTTT GCAGTACAT CAATGGGCGT	900
GGATAGCGGT TTGACTCAG GGGATTCCA AGTCTCCACC CCATTGACGT CAATGGGAGT	960
TGTTTTGGC ACCAAAATCA ACGGACTTT CCAAAATGTC GTAACAACCT CGCCCCATTG	1020
ACGCAATGG GCGGTAGGCG TGTAAGGTGG GAGGTCTATA TAAGCAGAGC TCGTTTAGTG	1080
AACCGTCAGA TGCGCTGGAG ACGCCATCCA CGCTGTTTTG ACCTCCATAG AAGACACGG	1140
GACCGATCCA GCGCTCGGAC TCTAGAGAT CCGGTACTCG AGGAACGTAA AAACCAAGAA	1200
GTTAACGTGT AAGTTAGTC TTTTGTCTT TTATTACAG TCCCGGATCC GGTGGTGTG	1260
CAATCAAAAG AACTGCTCCT CAGTGGATGT TGCCTTTACT TCTAGGCGTG TACGGAAGTG	1320
TTACTTCTGC TCTAAAAGCT GCGGAATTGT ACCCGGGGCC GCAATTCCCG GGAATCGAAA	1380
GAGCCTGCTA AAGCAAAAA GAAGTACCA TGTGTTTAC TTTGACCAAC AAGAACGTGA	1440
TTTTGTTGC CGGTCTGGGA GGCATTGGTC TGGACACAG CAAGGAGCTG CTCAGCGCG	1500
ATCCCGTGT TTTACACGT CGTACTGGG AAAACCTCG CGTTACCCAA CTTAATCGCC	1560
TTGCAGACA TCCCCCTTC GCCAGCTGCC GTAATAGCA AGAGGCCCGC ACCGATCGCC	1620
CTTCCCAACA GTTGCCGAGC CTGAATGGCG AATGGCGCTT TGCGTGTTT CCGGACCCAG	1680
AAGCGGTGCC GGAAGCTGG CTGGACTGG ATCTTCTGA GCGCGATACT GTGCTGCTC	1740
CCTCAAACTG GCAGATGCAC GCTTACGAT CGCCATCTA CACCAACGTA ACCTATCCCA	1800

TTACGGTCAA TCCGCGGTTT GTTCCACGG AGAATCCGAC GGGTTGTTAC TCGCTCACAT	1860
TTAATGTTGA TGAAGCTGG CTACAGGAAG GCCAGACGG AATTIATTTTT GATGGCGTTA	1920
ACTCGGGGTT TCATCTGTGG TGCACGGGG GCTGGGTGG TTACGGCCAG GACAGTCGTT	1980
TGCCGTCTGA ATTTGACCTG AGCGCATTTT TACGCGCGG AGAAAACCGC CTCGCGGTGA	2040
TGGTGTCTGG TTGGAGTGAC GGCAGTTATC TGAAGATCA GGATATGTGG CGGATGAGCG	2100
GCATTTTCCG TGACGTCTCG TTGCTGCATA AACGACTAC ACAAATCAGC GATTTCGATG	2160
TTGCCACTCG CTTTAATGAT GATTTCAGCC GCGCTGTACT GGAGGCTGAA GTTCAGATGT	2220
GCGCGAGTT GCGTGACTAC CTACGGGTAA CAGTTTCTTT ATGCGAGGT GAAACGCAGG	2280
TGCCCAGCG CACGCGGCTT TCGCGCGGT AAATTATCGA TGAGCGTGGT GGTATGCGG	2340
ATCGCGTCACT ACTACGTCG AACGTGAAA ACCCGAACT GTGAGCGGCC GAAATCCCGA	2400
ATCTCTATCG TCGGTTGGT GAAGTCACA CCGCGACGG CACGCTGATT GAAGCAGAAG	2460
CCTCGCATGT CCGTTTCCG GAGGTGGGA TTGAAATGG CTGCTGCTG CTGAACGGCA	2520
AGCGGTGCT GATTGAGGC GTTAACGTC ACGAGCATCA TCCTCTGCAT GGTGAGTCA	2580
TGGATGACGA GACGATGGT CAGGATATCC TGCTGATGAA CGACAACAAC TTTAACGCG	2640
TGCGCTGTC GCATTATCCG AACCATCCG TGTGTACAC GCTGTGCGAC CGCTACGGCC	2700
TGTATGTGGT GGATGAAGCC AATATTGAAA CCCACGGCAT GGTGCCAATG AATCGTCTGA	2760
CGGATGATCC GCGCTGGCTA CCGCGGATGA GCGAACGGT AACCGGAATG GTGACGGCG	2820
ATCGTAATCA CCGAGTGTG ATCATCTGGT CGCTGGGAA TGAATCAGGC CACGCGCTA	2880
ATCACGACGC GCTGTATCG TGGATCAAT CTGTGATCC TTCCCGCCCG GTGCGATGAT	2940
AAGCGCGGG AGCCGACACC ACGGCCAOCG ATATTATTTG CCCGATGTAC GCGCGCTGG	3000
ATGAAGACCA GCGCTTCCCG GCTGTGCGGA AATGTTCCAT CAATAATGG GTTTCGCTAC	3060
CTCGAGAGAC GCGCCCGCTG ATCCTTTGCG AATAAGCCCA CGCGATGGGT AACAGTCTTG	3120
GCGGTTTGGC TAAATACTGG CAGGCGTTTC GTCAGTATCC CCGTTTACAG GCGGCTTCG	3180
TCTGGGACTG GGTGGATCAG TCGCTGATTA AATATGATGA AAACGGCAAC CCGTGTCTGG	3240
CTTACGGCGG TGATTTTGGC GATACGCCGA ACGATGCCCA GTTCTGTATG AACGTTCTGG	3300
TCTTTGCCA CCGCACGCCG CATCCAGGCG TGACGGAAC AAAACACCAG CAGCAGTTTT	3360
TCCAGTTCCG TTTATCCGGG CAAACCATCG AAGTGACCAG CGAATACCTG TTCCGTCATA	3420
GCGATAACGA GCTCTGCAC TGGATGTGG CCGTGGATGG TAGCCGCTG GCAAGCGGTG	3480
AAGTGCTCT GGAATGCTCT CCACAAGGA AACAGTTGAT TGAAGTCCCT GAATACCGC	3540
AGCCGGAGAG CGCCGGGCAA CTCTGGCTCA CAGTACCGGT AGTGCAACCG AACCGCACG	3600
CATGCTCAGA AGCCGGGCGC ATCAGCGCTT GCGAGCAGTG CCGTCTGGCG GAAACCTCA	3660



GTGTGACGCT CCCGCGCGCG TCCACGCCA TCCGCGATCT GACCACCAGC GAAATGGATT	3720
TTTGCATCGA GCTGGGTAAT AAGCGTTGGC AATTAAACG CCACTCAGGC TTCTTTTCAC	3780
AGATGTGGAT TGGCGATAAA AAACRACTGC TGACGCGGCT GCGCGATCAG TTCACCCGTC	3840
CACCGCTGGA TAACGACATT GCGCTAAGTG AAGCGACCG CATTGACCT AACCCCTGGG	3900
TCCGAACGCTG GAAGCGCGCG GGCATTATCC AGGCCGAAGC AGCGTTGTTG CAGTGCAACG	3960
CAGATACACT TGCTGATGCG GTGCTGATT CAGCCGCTCA CGCGTGGCAG CATCAGGGGA	4020
AAACCTTATT TATCAGCCGG AAAACCTACC GGATTGATGG TAGTGGTCAA ATGGCGGATT	4080
CCGTTGATGT TGAAGTGGCG AGCGATACAC CGCATCCGGC GCGGATTGGC CTGAACTGCC	4140
AGCTGGGCGA GGTAGCAGAG CGGTAACCT GGCTCGGATT AGGGCCGCAA GAAACTATC	4200
CCGACCGCCT TACTGCCGCC TGTTTTGACC GCTGGGATCT GCCATTGTCA GACATGTATA	4260
CCCCGTACGT CTTCGCCGAG GAAAACGGTC TGCGCTGGCG GACGCGCGAA TTGAATTATG	4320
GCCACACCA GTGGCGCGGC GACTTCCAGT TCAACATCAG CGGTACAGT CAACAGCAAC	4380
TGATGGAAC CAGCCATGCG CATCTGCTGC ACGCGGAAGA AGGCACATGG CTGAATATCG	4440
ACGGTTTCCA TATGGGGATT GGTGGCGAGC ACTCCTGGAG CCGTCAGTA TCGCGCGAAT	4500
TACAGCTGAG CGCGCGTGCG TACCATTACC AGTTGGTCTG GTGTCAAAA TAATAATAAC	4560
CGGCGAGGCC ATGTCTGCCG GTATTTCGCG TAAGGAATC CATTATGTAC TATTTAAAAA	4620
ACACAACTT TTGGATGTTC GGTATTATCT TTTTCTTTTA CTTTTTATC ATGGGAGCCT	4680
ACTTCCCGTT TTTCGCGATT TGGCTACATG ACATCAACCA TATCAGCAA AGTGATACGG	4740
GTATTATTTT TGCCGCTATT TCTCTGTCT CGCTATTATT CCAACGCGTG TTTGGTCTGC	4800
TTTCTGCAA ACTCGGCTTC GACTCTAGCG GCGCGCGGG ATCCAGACAT GATAAGATAC	4860
ATTGATGAGT TTGGACAAAC CACAACTAGA ATGCAGTGAA AAAAATGCTT TATTTGTGAA	4920
ATTTGTGATG CTATTGCTTT ATTTGTAACC ATTATAAGCT GCAATAAACA AGTTAACAA	4980
AACAAITGCA TTCAITTTAT GTTTCAGGT CAGGGGAGG TGTGGGAGT TTTTTCGGAT	5040
CCTCTAGAGT CGAGTAGATA AGTAGCATGG CGGGTTAATC ATTAACACCA AGGAACCCCT	5100
AGTGATGGAG TTGGCCACTC CTCTCTGCG CGCTCGCTCG CTCCTGAGG CCGGCGGACC	5160
AAAGTCCGCC CGACGCCCGG GCTTTGCCCG GCGGCGCTCA GTGAGCGAG GAGCGCGCAG	5220
CAGATCTGGA AGTCTGTGAG GTACGATGAG ACCCGCACCA GGTGCAAGAC CTGCGAGTGT	5280
GGCGGTAAC ATATTAGGAA CCAACCTGTG ATGCTGATGT TGACCGAGGA GCTGAGGCC	5340
GATCACTTGG TGCTGGCGTG CACCGCGCT GAGTTTGGCT CTAGCGATGA AGATACAGAT	5400
TGAGGTACTG AAATGTGTGG GCGTGGCTTA AGGCTGGGAA AGAATATATA AGGTGGGGT	5460
CTTATGTAGT TTTGTATCTG TTTTGACGA GCGCGCGCG CCAATGACAC CAACTGTTT	5520

GATGGAAGCA TTGTAGCTC ATATTGACA ACGCGCATGC CCCCATGGGC CGGGGTGCGT	5580
CAGAAATGTA TGGGCTCCAG CATTGATGTT GCGCCGCTCC TGCCCGCAAA CTCTACTACC	5640
TTGACCTACG AGACCGGTGC TGGAAACGCC TTGGAGACTG CAGCCTCCGC CGCGCGTTCA	5700
GCGCGTGACG CCACCGCCCG CGGGATTGTG ACTGACTTTG CTTTCCTGAG CCCGCTTGCA	5760
AGCAGTGACG CTTCCCGTTC ATCCGCCCGC GATGACAAGT TGACCGCTCT TTTGGCACA	5820
TTGGATTCTT TGACCCGCGA ACTTAATGTC GTTTCCTCAG AGCTGTTGGA TCTGCGCCAG	5880
CAGGTTTCTT CCTGAAGGC TTCTCCCTCT CCCAATGCGG TTTAAACAT AATAAAAAA	5940
CCAGACTCTG TTTGGATTG GATCAAGCAA GTGCTTGCT GTCTTTATT AGGGGTTTG	6000
CGCGCGCGGT AGGCCCGGGA CCAGCGGTCT CGGTCTGTGA GGTCTCTGTG TATTTTTTCC	6060
AGGACGTGTT AAGGTGACT CTGGATGTT AGATACATG GCATAAGCCC GTCTCTGGGG	6120
TGGAGGTAGC ACCACTGCAG AGCTTCATGC TCGGGGGTGG TGTGTAGAT GATCCAGTGG	6180
TAGCAGGAGC GCTGGGCGTG GTGCCAAAA ATGCTTTCA GTAGCAAGCT GATGCCAGG	6240
GGCAGGCCCT TGGTCTAAGT GTTTACAAAG CGGTTAAGCT GGGATGGGTG CATACGTGGG	6300
GATATGAGAT GCATCTTGA CTGTATTTT AGGTTGGCTA TGTTCGCCAG CATATCCCTC	6360
CGGGGATTCA TGTGTGCGAG AACCACCAGC ACAGTGTATC CGGTGCACCT GGGAAATTTG	6420
TCATGTAGCT TAGAAGGAAA TGCGTGGAG AACTGGAGA CGCCCTGTG ACCTCCAAGA	6480
TTTTCCATGC ATTGCTCCAT AATGATGGCA ATGGGCCAC GGGCGGCGC CTGGGCGAAG	6540
ATATTCTGCG GATCACTAAC GTCATAGTTG TGTCCAGGA TGAGATCGTC ATAGGCCATT	6600
TTTACAAAGC GGGGGCGGAG GGTGCCAGAC TCGGGTATAA TGCTTCCATC CGGCCAGGG	6660
GCGTAGTACT CCTCACAGAT TTGCATTTCC CAGCCTTTGA GTTCAGATGG GGGGATCATG	6720
TTACTCTGCG GGGCGATGAA GAAACGGTT TCCGGGGTAG GGCAGATCAG CTGGGAAGAA	6780
AGCAGGTTCC TGAGCAGCTG CGACTTACCG CAGCCGGTGG GCGCGTAAAT CACACCTATT	6840
ACCGGGTGCA ACTGGTAGTT AAGAGAGCTG CAGCTGCCGT CATCCCTGAG CAGGGGGGCC	6900
ACTTGTTGAA GCATGTCCTT GACTGGCATG TTTCCCTGA CCAATCCGC CAGAAGGCGC	6960
TGCGCGCCCA GCGATAGCAG TTCTTGCAAG GAAGCAAAGT TTTTCAACGG TTTGAGACCG	7020
TCGCGCGTAG GCATGCTTTT GAGCCTTTGA CCAAGCAGTT CCAGCGGGTC CCACAGCTCG	7080
GTACCTGCT CTACGGCATC TCGATCCAGC ATATCTCCTC GTTTCGCGGG TTGGGGGGGC	7140
TTTCGCTGTA CGGCAGTAGT CGGTGCTGCT CCAGACGGGC CAGGGTCATG TCTTTCCAG	7200
GGCGCAGGTT CCTGCTCAGC GTAGTCTGGG TCACGCTGAA GGGGTGCGCT CGGGGCTGCG	7260
CGTGGCCAG GGTGCGCTTG AGGCTGGTCC TGCTGCTGCT GAAGCGCTGC CGGTCTTCGC	7320
CCTCGCGGTC GGCACGGTAG CATTGACCA TGGTGTGATA GTCCAGCCCC TCCGCGGCGT	7380

GGCCCTTGGC GGCAGCTTG CCCTTGGAGG AGGCGCGCA CGAGGGGCGAG TGCAGACTTT	7440
TGAGGGCGSTA GAGCTTGGGC GCGAGAAATA CCGATTCCGG GGAGTAGGCA TCCGGCGCGC	7500
AGGCCCCGCA GACGGTCTCG CATTCCACGA GCCAGGTGAG CTCTGGCCGT TCGGGGTCAA	7560
AAACCAGGTT TCCCCATGC TTTTGTATGC GTTCTTACG TCTGGTTTCC ATGAGCCGGT	7620
GTCCACGCTC GGTGACGAAA AGGCTGTCCG TGTCCCCGTA TACAGACTTG AGAGGCCGTG	7680
CCTCGACCGA TGCCCTTGAG AGCCTTCAAC CCAGTCAGCT CCTTCCGGTG GCGCGGGGCG	7740
ATGACTATCG TCGCCGCACT TATGACTGTC TTCTTTATCA TGCAACTCGT AGGACAGGTG	7800
CCGGCAGCGC TCTGGGTGAT TTTCCGGGAG GACCGCTTTC GCTGGAGCGC GACGATGATC	7860
GGCCTGTCCG TTGCGGTATT CGGAATCTTG CACGCCCTCG CTCAGCCCTT CGTCACTGGT	7920
CCGCGCCACA AACGTTTCCG CGAGAAGCAG GCCATTATCG CCGGCATGGC GCGCGACCGG	7980
CTGGGTACG TCTTGCTGGC GTTCCGACG CGAGGCTGGA TGGCCTTCCC CATTATGATT	8040
CTTCTCGCTT CCGGCGGCAT CGGGATGCCC GCGTTGAGG CCATGCTGTC CAGGCAGGTA	8100
GATGACGACC ATCAGGGACA GCTTCAAGGA TCGCTCGGG CTCTTACCGC CCTAACTTCG	8160
ATCACTGGAC CGCTGATCGT CACGGCGATT TATGCGCCCT CGGCGAGCAC ATGGAACGGG	8220
TTGGCATGGA TTGTAGGGCG CGCCCTATAC CTGTCTGCCC TCCCCGGTT GCGTCGGGCT	8280
GCATGGAGCC GGGCCACCTC GACCTGAATG GAAGCGCGCG GCACCTCGCT AACGGATTCA	8340
CCACTCCAAG AATTGGAGCC AATCAATTCT TGCGGAGAAC TGTGAATGCG CAAACCAACC	8400
CTTGGCAGAA CATATCCATC GCGTCCGCCA TCTCCAGCAG CCGCACGGGG CGCATCTCGG	8460
CGACGGTTGG GTTCTGGCCA CGGGTGCGCA TGATCGTGCT CCTGTGTTG AGGACCGCGC	8520
TAGGCTGGCG GGGTTGCCIT ACTGGTTAGC AGAATGAATC ACCGATACGC GAGCGAAGCT	8580
GAAGCGACTG CTGCTGCAAA ACCTCTCGGA CCTGAGCAAC AACATGAATG GTCTTCGGTT	8640
TCCGTGTTTC GTAAAGTCTG GAAACGGGGA AGTCAGCGCC CTGCACCAIT ATGTTCGGGA	8700
TCGTGCTGCG AGGATGCTGC TGGCTACCCT GTGGAACACC TACATCTGTA TTAACGAAGC	8760
CTTTCTCAAT GCTCAGCGTG TAGGTATCTC AGTTGGGTGT AGGTGCTTCC CTCGAAGCTG	8820
GGCTGTGTGC ACGAACCCCC CGTTCAGCCC GACCGCTGCG CCTTATCCGG TAACTATCGT	8880
CTTGAGTCCA ACCCGGTAAG ACACGACTTA TCGCACTGG CAGCAGCCAC TGGTAACAGG	8940
ATTAGCAGAG CGAGGTATGT AGGCGGTGCT ACAGAGTCTT TGAAGTGGTG GCCTAACTAC	9000
GGCTACACTA GAAGGACAGT ATTTGGTATC TGCGCTCTGC TGAAGCCAGT TACCTTCGGA	9060
AAAGAGTTG GTAGCTCTTG ATCCGGCAAA CAACCCACCG CTGCTAGCGG TGGTTTTTTT	9120
GTTTGCAGGC AGCAATTAC GCGCAGAAAA AAAGGATCTC AAGAAGATCC TTTGATCTTT	9180
TCTACGGGGT CTGACGCTCA GTGGAACGAA AACTCAGGTT AAGGGATTTT GGTCATGAGA	9240

26

TTATCAAAAA	GGATCTTCAC	CTAGATCCTT	TTAAATTAAT	AATGAAGTTT	TAAATCAATC	9300
TAAAGTATAT	ATGAGTAATC	TTGGTCTGAC	AGTTACCAAT	GCTTAATCAG	TGAGGCACCT	9360
ATCTCAGCGA	TCTGTCTATT	TGGTTCATCC	ATAGTTGCCT	GACTCCCGGT	CGTGTAGATA	9420
ACTACGATAC	GGGAGGGCTT	ACCATCTGGC	CCCAGTCTCG	CAATGATACC	GCGAGACCCA	9480
CGCTCAGCGG	CTCCAGATTT	ATCAGCAATA	AACCAAGCCG	CCGGAAGGGC	CGAGCGCAGA	9540
AGTGTCTCTG	CAACTTTTAT	CGCTCCCATC	CAGTCTATTA	ATTGTTGCCG	GGAAGCTAGA	9600
GTAAAGTAGT	CGCCAGTTAA	TAGTTTGCGC	AACGTTGTTG	CCATTGCTGC	AGGCATCGTG	9660
GTGTCAAGCT	CGTGGTTTGG	TATGGCTTCA	TTCAAGTCCG	GTTCCCAACG	ATCAAGGCGA	9720
GTTACATGAT	CCCCCATGTT	GTGCAAAAAA	CGGCTTAGCT	CCTTCGGTCC	TCCGATCGTT	9780
GTGAGAAGTA	AGTTGGCCGC	AGTGTATATC	CTCATGGTTA	TGGCAGCACT	GCATAATTCT	9840
TTTACTGTCA	TGCCATCGGT	AAGATGCTTT	TCTGTGACTG	GTGAGTACTC	AACCAAGTCA	9900
TCTGTAGAAT	AGTGTATCGG	CGCAGCGAGT	TGCTCTTGCC	CGGCGTCAAC	ACGGGATAAT	9960
ACCGCGCCAC	ATAGCAGAAC	TTTAAAGTGT	CTCATCATTG	GAAAACGTTT	TTCCGGGCGA	10020
AAACTCTCAA	GGATCTTACC	GCTGTTGAGA	TCCAGTTCEA	TGTAACCCAC	TGTTGCACCC	10080
AACTGATCTT	CAGCATCTTT	TACTTTTACC	AGCGTTTCTG	GGTGACCAAA	AACAGGAAGG	10140
CAAAATGCCG	CAAAAAAGGG	AATAAGGGCG	ACACGGAAAT	GTTGAATACT	CATACTCTTC	10200
CTTTTTCAA	ATTATTGAAG	CATTATTCAG	GGTTATTGTC	TGATGACGGG	ATACATATTT	10260
GAATGTATTT	AGAAAAATAA	ACAAATAGGG	GTTCGGCGCA	CATTTCCTCG	AAAAGTGCCA	10320
CCTGACGTCT	AAGAAACCAT	TATTATCATG	ACATTAACTT	ATAAAAAATG	GCCTATCACG	10380
AGGCCCTTTC	GTCTTCAA					10398

## (2) INFORMATION FOR SEQ ID NO:2:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 20 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: other nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

TATTTAAGCC CGAGTGAGCT

20

What is claimed is:

1. A method for production of recombinant adeno-associated virus (AAV) comprising the steps of:
  - (a) introducing into a selected host cell a first vector comprising T7 polymerase under control of sequences which drive expression thereof,
    - a second vector comprising AAV rep and cap genes under control of T7 promoter sequences which drive expression of rep and cap; and
    - a third vector comprising from 5' to 3', a cassette consisting essentially of a 5' AAV inverted terminal repeat (ITR), a selected minigene, and a 3' AAV ITR;
  - (b) culturing the host cell under conditions which permit replication and packaging of recombinant AAV; and
  - (c) recovering the recombinant AAV.
2. The method according to claim 1 wherein at least one of the vectors is an adenovirus and the host cell is a 293 cell.
3. The method according to claim 1 wherein the first vector is a recombinant adenovirus.
4. The method according to claim 1 wherein the second vector is a recombinant adenovirus.
5. The method according to claim 1 wherein the third vector further comprises adenoviral sequences flanking the cassette.

6. The method according to any of claims 1 to 5 wherein the minigene contains a transgene which is a marker gene.

7. The method according to claim 6 wherein the minigene contains a transgene which is a therapeutic gene.

8. A method for production of recombinant adeno-associated virus (AAV) comprising the steps of:

(a) providing a host cell which expresses T7 polymerase;

(b) introducing into the host cell a first vector which comprises AAV rep and cap genes under control of T7 promoter sequences;

(c) introducing into the host cell a second vector comprising a cassette consisting essentially of 5' AAV inverse terminal repeat (ITR), a selected minigene, and 3' AAV ITR; and

(d) culturing the host cell under conditions which permit replication and packaging of a recombinant AAV.

9. The method according to claim 8 wherein step (b) comprises the step of transfecting the host cell with a vector comprising the T7 promoter and the AAV rep and cap genes.

10. The method according to claim 8 wherein step (b) comprises the step of infecting the host cell with a recombinant adenovirus comprising the T7 promoter sequences, and the AAV rep and cap genes.

11. The method according to claim 8 wherein step (c) comprises transfecting the host cell with a vector comprising the cassette.

12. The method according to claim 8 wherein step (c) comprises infecting the host cell with a recombinant adenovirus comprising the cassette flanked by adenovirus sequences.

13. A method for production of recombinant adeno-associated virus (AAV) comprising the steps of:

(a) providing a host cell stably transfected with AAV *rep* and *cap* genes under control of T7 promoter sequences;

(b) introducing into the host cell a vector comprising T7 polymerase;

(c) introducing into the host cell with vector comprising a cassette consisting essentially of a 5' AAV inverse terminal repeat (ITR), a selected minigene, and a 3' AAV ITR; and

(d) culturing the host cell under conditions which permit replication and packaging of a recombinant AAV.

14. The method according to claim 13 wherein step (b) comprises the step of transfecting the host cell with a vector comprising the T7 polymerase gene.

15. The method according to claim 13 wherein step (b) comprises the step of infecting the host cell with a recombinant adenovirus comprising the T7 polymerase gene under control of regulatory sequences controlling expression thereof.

16. The method according to claim 13 wherein step (c) comprises the step of transfecting the host cell with a vector comprising the cassette.

17. The method according to claim 13 wherein step (c) comprises the step of infecting the host cell with a recombinant adenovirus comprising the cassette flanked by adenovirus sequences.

18. A method for production of recombinant adeno-associated virus (AAV) comprising the steps of:

(a) providing a host cell comprising a cassette consisting essentially of 5' AAV inverse terminal repeats (ITR), a selected minigene, and a 3' AAV ITR;

(b) introducing into the host cell a vector comprising AAV *rep* and *cap* genes under control of T7 promoter sequences;

(c) introducing into the host cell a vector comprising the T7 polymerase; and

(d) culturing the host cell under conditions which permit replication and packaging of a recombinant AAV.

19. The method according to claim 18 wherein step (b) comprises the step of transfecting the host cell with a plasmid vector.

20. The method according to claim 18 wherein step (b) comprises the step of infecting the host cell with a recombinant adenoviral vector.



21. The method according to claim 18 wherein step (c) comprises the step of transfecting the host cell with a plasmid vector containing the T7 polymerase under control of regulatory sequences which direct expression thereof.

22. The method according to claim 18 wherein step (c) comprises the step of infecting the host cell with a recombinant adenovirus comprising the T7 polymerase under control of regulatory sequences which direct expression thereof.

23. A method for production of recombinant adeno-associated virus (AAV) comprising the steps of:

(a) providing a host cell stably transfected with a cassette consisting essentially of 5' AAV inverse terminal repeats (ITR), a selected minigene, and a 3' AAV ITR and a plasmid comprising AAV *rep* and *cap* genes under control of T7 promoter sequences;

(b) introducing into the host cell a vector comprising the T7 polymerase; and

(c) culturing the host cell under conditions which permit replication and packaging of a recombinant AAV.

24. A method for production of recombinant adeno-associated virus (AAV) comprising the steps of:

(a) providing a host cell stably transfected with a cassette consisting essentially of 5' AAV inverse terminal repeats (ITR), a selected minigene, and a 3' AAV ITR and a plasmid comprising T7 polymerase;

(b) introducing into the host cell a vector comprising AAV *rep* and *cap* genes under control of T7 promoter sequences; and

(c) culturing the host cell under conditions which permit replication and packaging of a recombinant AAV.

25. A method for production of recombinant adeno-associated virus (AAV) comprising the steps of:

(a) providing a host cell stably transfected with

(i) a cassette consisting essentially of 5' AAV inverse terminal repeats (ITR), a selected minigene, and a 3' AAV ITR;

(ii) a plasmid comprising T7 polymerase under control of sequences which regulate expression thereof, said sequences comprising an inducible promoter; and

(iii) a plasmid AAV *rep* and *cap* genes under control of T7 promoter sequences; and

(b) inducing expression of said T7 promoter.

26. A recombinant adenovirus produced according to the method of any one of claims 1 - 25.

1/4




FIG. 1

2 / 4




FIG. 2

3/4




FIG. 3

4 / 4




FIG. 4

# INTERNATIONAL SEARCH REPORT

International Application No  
PC1/US 97/15716

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 6 C12N15/86 C12N7/01

According to International Patent Classification(IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the texts searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	LEONARD, C. J. ET AL: "Cloning, expression, and partial purification of Rep78: an adeno - associated virus replication protein" VIROLOGY (1994), 200(2), 566-73 CODEN: VIRLAX; ISSN: 0042-6822, 1994, XP002052542 see the whole document	26
X	WO 95 13392 A (OHIO MED COLLEGE ; TARGETED GENETICS CORP (US); TREMPER JAMES P (US)) 18 May 1995 see page 8, line 16 - page 9, line 1; claims 1-18	26
X	WO 96 17947 A (TARGETED GENETICS CORP ; ALLEN JAMES M (US)) 13 June 1996 see the whole document	26

-/-



Further documents are listed in the continuation of box C.



Patent family members are listed in annex

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document published on or after the international filing date

"L" documents which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document relating to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

19 January 1998

Date of mailing of the international search report

30/01/1998

Name and mailing address of the ISA  
European Patent Office, P.B. 5618 Patentaan 2  
NL - 2280 HV Rijswijk  
Tel: (+31-70) 340-2040, Tx. 31 651 epo NL,  
Fax: (+31-70) 340-3016

Authorized officer

Hornig, H

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 97/15716

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96 14061 A (CELL GENESYS INC) 17 May 1996 see page 20, line 20 - page 21, line 24 ---	26
X	WO 96 13598 A (UNIV PENNSYLVANIA ;WILSON JAMES M (US); KELLEY WILLIAM M (US); FIS) 9 May 1996 cited in the application see page 2, line 19 - page 22, line 5 ---	26
X	WO 96 12010 A (DEUTSCHES KREBSFORSCH ;MAX PLANCK GESELLSCHAFT (DE); HOELSCHER CHR) 25 April 1996 see the whole document ---	26
X	WO 95 14771 A (US HEALTH ;GENETIC THERAPY INC-(US)) 1 June 1995 see the whole document ---	26
X	WO 95 13365 A (TARGETED GENETICS CORP ;UNIV JOHNS HOPKINS (US); FLOTTE TERENCE R) 18 May 1995 see the whole document ---	26
X	WO 94 13788 A (UNIV PITTSBURGH) 23 June 1994 see the whole document ---	26
X	CLARK K R ET AL: "CELL LINES FOR THE PRODUCTION OF RECOMBINANT ADENO-ASSOCIATED VIRUS" HUMAN GENE THERAPY, vol. 6, no. 10, 1 October 1995, pages 1329-1341, XP000569718 see the whole document ---	26
X	KOTIN R M: "PROSPECTS FOR THE USE OF ADENO-ASSOCIATED VIRUS AS A VECTOR FOR HUMAN GENE THERAPY" HUMAN GENE THERAPY, vol. 5, 1994, pages 793-801, XP000651491 cited in the application see the whole document ---	26
A	WO 94 26911 A (UNIV OHIO) 24 November 1994 see the whole document ---	1-26
A	WO 91 00905 A (US ARMY) 24 January 1991 see the whole document ---	1-26

-/--



## INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 97/15716

C. (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	A. LIEBER ET AL.: "High level gene expression in mammalian cells by a nuclear T7-phage RNA polymerase" NUCLEIC ACIDS RESEARCH, vol. 17, no. 21, - 1989 IRL PRESS LIMITED, OXFORD, ENGLAND, pages 8485-8493, XP002052543 cited in the application see the whole document ----	1-26
A	FUERST T R ET AL: "EUKARYOTIC TRANSIENT-EXPRESSION SYSTEM BASED ON RECOMBINANT VACCINIA VIRUS THAT SYNTHESIZES BACTERIOPHAGE T7 RNA POLYMERASE" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 83, no. 21, 1 November 1986, pages 8122-8126, XP000563743 cited in the application see the whole document ----	1-26
A	ELROY-STEIN O ET AL: "CYTOPLASMIC EXPRESSION SYSTEM BASED ON CONSTITUTIVE SYNTHESIS OF BACTERIOPHAGE T7 POLYMERASE IN MAMMALIAN CELLS" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 87, no. 17, 1 September 1990, pages 6743-6747, XP000563742 cited in the application see the whole document ----	1-26
P,X	WO 97 00947 A (RHONE POULENC RORER SA ; LATTI MARTINE (FR); ORSINI CECILE (FR); PE) 9 January 1997 see the whole document -----	26

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No  
PCT/US 97/15716

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9513392 A	18-05-95	AU 678867 B	12-06-97
		AU 8130994 A	29-05-95
		EP 0728214 A	28-08-96
		JP 9510602 T	28-10-97
WO 9617947 A	13-06-96	AU 4596396 A	26-06-96
		CA 2207927 A	13-06-96
		EP 0796339 A	24-09-97
WO 9614061 A	17-05-96	AU 4109296 A	31-05-96
		CA 2204357 A	17-05-96
		EP 0797436 A	01-10-97
WO 9613598 A	09-05-96	AU 4405596 A	23-05-96
		EP 0797678 A	01-10-97
WO 9612010 A	25-04-96	DE 4436665 A	18-04-96
		DE 4436664 A	04-07-96
		CA 2202664 A	25-04-96
		EP 0785991 A	30-07-97
WO 9514771 A	01-06-95	US 5693531 A	02-12-97
		CA 2176600 A	01-06-95
		EP 0736092 A	09-10-96
		JP 9505480 T	03-06-97
WO 9513365 A	18-05-95	AU 1129395 A	29-05-95
		CA 2176117 A	18-05-95
		EP 0733103 A	25-09-96
		JP 9509564 T	30-09-97
		US 5658776 A	19-08-97
WO 9413788 A	23-06-94	US 5478745 A	26-12-95
		EP 0673415 A	27-09-95
		JP 8504102 T	07-05-96
WO 9426911 A	24-11-94	US 5591601 A	07-01-97
		AU 6949894 A	12-12-94
		CA 2162867 A	24-11-94
		EP 0751998 A	08-01-97

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 97/15716

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9426911 A		JP 8510132 T	29-10-96
WO 9100905 A	24-01-91	US 5135855 A	04-08-92
		AT 157701 T	15-09-97
		AU 642657 B	28-10-93
		AU 6034490 A	06-02-91
		CA 2063427 A	08-01-91
		DE 69031389 D	09-10-97
		EP 0484374 A	13-05-92
		JP 2525289 B	14-08-96
		JP 5501048 T	04-03-93
		US 5126251 A	30-06-92
WO 9700947 A	09-01-97	FR 2735789 A	27-12-96
		AU 6363996 A	22-01-97